Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Salvianolic Acid on AIS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute ischemic stroke with the first onset, or a history of cerebral infarction but with a modified Rankin Scale (mRS) score ≤1, onset within 72h;~2. CT examination to rule out cerebral hemorrhage;~3. With clear signs of nervous system positioning, the National Institutes of Health Stroke Scale (NIHSS) score ≥ 4~Exclusion Criteria:~1. Diseases with bleeding tendency;~2. Liver and kidney dysfunction;~3. Malignant tumors or those undergoing anti-tumor treatment;~4. Allergic physique, allergic to aspirin or Salvianolic Acid;~5. Heart failure, multiple system failure;~6. Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- salvianolic acid group (Type: ACTIVE_COMPARATOR): salvianolic acid group 100mg+0.9%NaCl 250ml, injection, 14 days
- 0.9% NaCl (Type: PLACEBO_COMPARATOR): 0.9%NaCl 250ml, injection, 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).